Renal Denervation Devices Market Size
Study Period | 2021 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 36.89 % |
Fastest Growing Market | North America |
Largest Market | Europe |
Market Concentration | High |
Major Players*Disclaimer: Major Players sorted in no particular order |
Renal Denervation Devices Market Analysis
The renal denervation devices market is expected to register a CAGR of 36.89% during the forecast period.
- The outbreak of the COVID-19 pandemic impacted the renal denervation devices market as hospitals and healthcare services significantly reduced due to social distancing measures taken by countries across the world. During the COVID-19 outbreak, many medical device manufacturers either delayed or postponed the launch of their devices due to resource and fund crunch, negatively impacting the renal denervation devices market. However, despite these setbacks, rising levels of hypertension coupled with high alcohol consumption during the pandemic may contribute to the market recovery over the foreseeable future. For instance, according to the National Institute on Alcohol Abuse and Alcoholism, the quantity of alcohol sold in 15 US states rose by 4% from January to August 2020 as compared to a year earlier, which could increase the risk of hypertension and stimulate the use of renal denervation devices. Hence, the studied market is anticipated to witness growth in the coming years owing to factors such as a rise in product sales, new product launches, and an increase in hypertension-related health issues.
- Major factors responsible for the growth of the renal denervation devices market include the rising prevalence of hypertension and the long-lasting effect of the procedure. The prevalence of hypertension has been observing a significant rise over the past few years. According to the August 2021 update from the WHO, around 1.28 billion people aged between 30 and 79 years are affected by hypertension globally. An increase in the number of cases of hypertension is expected to create demand for renal denervation devices during the forecast period. Some major reasons for an increase in the prevalence of hypertension are the increasing geriatric population, high sodium and low potassium intake, rising cases of obesity, increasing alcohol consumption in low- and middle-income countries, physical inactivity, and the lack of a balanced diet.
- Additionally, increasing the patient pool of other chronic diseases like obesity among children and adults will power renal denervation market growth through the forecast period. As per the WHO's statistics, over 39 million children aged below 5 years were overweight in 2021. This condition is likely to push the demand for renal nerve denervation therapy, as high leptin levels in obese people can trigger the growth of blood vessels in the hypothalamus, thereby causing hypertension. A rise in the level of daily alcohol consumption will further drive the market growth, as regular drinking may lead to hypertension as it is possible that alcohol may stimulate adrenals to release adrenaline, resulting in increased heart rate, cardiac output, and systolic blood pressure.
- Furthermore, an increase in clinical studies and research and development associated with renal denervation devices and the long-term benefits of renal denervation procedures are anticipated to drive market growth. For instance, as per the article published in April 2022 in Nature journal, more than 80% of Thai patients with resistant hypertension experienced the success of the renal nerve denervation outcome, which was sustained over a longer follow-up without any intervention-related side effects.
- Hence, due to the rise in the prevalence of hypertension and the long-term benefits offered by renal denervation devices, the studied market is anticipated to witness growth in the studied market over the forecast period. However, stringent approval processes for renal denervation devices and reimbursement systems and painful procedures are anticipated to restrain the market growth over the forecast period.
Renal Denervation Devices Market Trends
This section covers the major market trends shaping the Renal Denervation Devices Market according to our research experts:
The Ultrasound-based Segment is Expected to be the Fastest-growing Segment Over the Forecast Period
The ultrasound-based renal denervation devices are a minimally invasive procedure that uses ultrasound to ablate nerves in the wall of the renal arteries. It disrupts the transmission of nerve impulses to and from the kidney and lowers blood pressure. The ultrasound-based renal denervation devices are anticipated to witness growth in the market owing to the factors such as a rise in the prevalence of hypertension and an increase in demand for ultrasound-based renal denervation devices. For instance, as per the June 2022 update from WHO, it is estimated that at least one in four adults in India has hypertension, and only about 12% of them have their blood pressure under control. Such high blood pressure is linked with high cholesterol levels, and its growing incidence could bolster product demand for ultrasound-based renal denervation devices.
Furthermore, a rise in research studies of ultrasound-based renal denervation devices is anticipated to boost market growth over the forecast period. For instance, as per an article published in October 2021 by PubMed, an ultrasound In REsistant hypertension (REQUIRE) trial was designed to assess the BP-lowering efficacy of renal denervation in patients with resistant hypertension from Japan and South Korea. Thus, postive outcome of such studies may results into new treatment option, thereby increasing the segmental growth over the forecast period.
Innovative product launches and collaborations are some of the initiatives being undertaken in this segment by key market players to reinforce their presence in the global market. For instance, in December 2020, ReCor Medical Inc. received the US FDA's Breakthrough Device Designation for its innovative Paradise Ultrasound Renal Denervation System, designed to ablate the renal nerve using ultrasound energy. Hence, due to the rise in the prevalence of hypertension, the increase in research activities associated with ultrasound-based renal denervation devices and rise in product approvals, the studied segment is anticipated to witness growth in the market over the forecast period.
Europe is Anticipated to Witness a Significant Growth in the Renal Denervation Devices Market Over the Forecast Period
Europe is likely to witness significant growth in the renal denervation devices market owing to the factors such as a rise in the prevalence of hypertension, an increase in technological advancements, and the long-lasting effect of the procedure. For instance, as per the Office of Health Improvement and Disparities statistics, the prevalence of hypertension in England was 8,457,600 in 2021. Moreover, as per a Survey conducted in 2021 in Italy, 73.6% of participants reported being aware of their BP status, 42.3% reported a diagnosis of hypertension, and 41.4% were taking antihypertensive medications. The prevalence of self-reported hypertension was also greater in men than women. Thus, increasing the incidence of hypertension is one of the key factors responsible for the region's growth.
Furthermore, the major factor driving the market's growth is growing R&D activities to develop efficient devices. The rise in the number of product launches in the region will also contribute to the market's growth. For instance, in October 2021, ReCor Medical Inc. launched the ultrasound renal denervation system in Europe, which is likely to be used to treat uncontrolled hypertension in Germany. Hence, due to the rise in the prevalence of hypertension and the increase in product approvals for renal denervation devices, Europe is anticipated to witness growth over the forecast period.
Renal Denervation Devices Industry Overview
The market is consolidated due to the presence of some major market players. Various strategies, such as R&D, M&A, and product launch, are being adopted by key companies to strengthen their market position.
Some of the market players are Abbott, Ablative Solutions, Boston Scientific Corporation, CardioSonic, Kona Medical, Medtronic PLC, Mercator MedSystems, ReCor Medical, and Symple Surgical.
Renal Denervation Devices Market Leaders
-
Boston Scientific Corporation
-
Medtronic PLC
-
ReCor Medical
-
Symple Surgical
-
Mercator MedSystems
*Disclaimer: Major Players sorted in no particular order
Renal Denervation Devices Market News
- May 2022: Medtronic PLC released data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral Renal Denervation (RDN) system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials.
- March 2022: ReCor Medical Inc., a fully owned subsidiary of Otsuka Medical Devices Co., Ltd, completed the enrollment in their RADIANCE-II pivotal trial of the Paradise Ultrasound Renal Denervation (uRDN) System for the treatment of uncontrolled hypertension.
Renal Denervation Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Hypertension
- 4.2.2 Long Lasting Effect of the Procedure
-
4.3 Market Restraints
- 4.3.1 Painful Procedure
- 4.3.2 Stringent Approval Process for Renal Denervation Devices and Reimbursement Systems
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Technology
- 5.1.1 Radiofrequency-based
- 5.1.2 Ultrasound-based
- 5.1.3 Micro-infusion-based
-
5.2 Geography
- 5.2.1 North America
- 5.2.1.1 United States
- 5.2.1.2 Canada
- 5.2.1.3 Mexico
- 5.2.2 Europe
- 5.2.2.1 Germany
- 5.2.2.2 United Kingdom
- 5.2.2.3 France
- 5.2.2.4 Italy
- 5.2.2.5 Spain
- 5.2.2.6 Rest of Europe
- 5.2.3 Asia-Pacific
- 5.2.3.1 China
- 5.2.3.2 Japan
- 5.2.3.3 India
- 5.2.3.4 Australia
- 5.2.3.5 South Korea
- 5.2.3.6 Rest of Asia-Pacific
- 5.2.4 Rest of the World
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Medtronic PLC
- 6.1.2 Abbott Laboratories (St. Jude Medical Inc.)
- 6.1.3 Otsuka Holdings Co. Ltd (ReCor Medical Inc.)
- 6.1.4 Ablative Solutions Inc.
- 6.1.5 Mercator MedSystems
- 6.1.6 Terumo Corporation
- 6.1.7 Symple Surgical
- 6.1.8 Boston Scientific Corporation
- 6.1.9 SoniVie
- 6.1.10 Recor Medical Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityRenal Denervation Devices Industry Segmentation
As per the scope of the report, renal denervation devices are one of several innovative device-based interventional therapies that help control blood pressure. It is safe, minimally invasive, and does not leave any implants behind. The renal denervation procedure uses radiofrequency ablation to burn the nerves in the renal arteries. This process causes a reduction in nerve activity, which decreases blood pressure.
The Renal Denervation Devices Market is segmented by technology (radiofrequency-based, ultrasound-based, and micro-infusion-based) and geography (North America, Europe, Asia-Pacific, and Rest of the World). The market sizes and forecasts are provided in terms of value (USD million) for all the above segments.
By Technology | Radiofrequency-based | |
Ultrasound-based | ||
Micro-infusion-based | ||
Geography | North America | United States |
Canada | ||
Mexico | ||
Geography | Europe | Germany |
United Kingdom | ||
France | ||
Italy | ||
Spain | ||
Rest of Europe | ||
Geography | Asia-Pacific | China |
Japan | ||
India | ||
Australia | ||
South Korea | ||
Rest of Asia-Pacific | ||
Geography | Rest of the World |
Renal Denervation Devices Market Research FAQs
What is the current Renal Denervation Devices Market size?
The Renal Denervation Devices Market is projected to register a CAGR of 36.89% during the forecast period (2024-2029)
Who are the key players in Renal Denervation Devices Market?
Boston Scientific Corporation, Medtronic PLC, ReCor Medical, Symple Surgical and Mercator MedSystems are the major companies operating in the Renal Denervation Devices Market.
Which is the fastest growing region in Renal Denervation Devices Market?
North America is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Renal Denervation Devices Market?
In 2024, the Europe accounts for the largest market share in Renal Denervation Devices Market.
What years does this Renal Denervation Devices Market cover?
The report covers the Renal Denervation Devices Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Renal Denervation Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Renal Denervation Devices Industry Report
Statistics for the 2024 Renal Denervation Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Renal Denervation Devices analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.